Preview

Анналы хирургической гепатологии

Расширенный поиск

Терапия гепатоцеллюлярного рака: реалии и перспективы

https://doi.org/10.16931/1995-5464.2020227-38

Полный текст:

Аннотация

В статье рассмотрены результаты клинических исследований и перспективы периоперационной системной терапии рака печени, а также эффективность сочетания с локорегионарными методами. Отдельное внимание уделено терапии гепатоцеллюлярного рака в 1-й и 2-й линии как уже одобренными в РФ препаратами (мультикиназные ингибиторы, моноклональные антитела крецептору фактора роста эндотелия сосудов, ингибиторы контрольных точек), так и идущим клиническим исследованиям. Рассмотрены перспективные комбинации иммунотерапии с мультикиназными и (или) ангиогенными ингибиторами, потенциальные предикторы эффективности иммунотерапии гепатоцеллюлярного рака, а также особенности терапии после ортотопической трансплантации печени и на фоне некомпенсированного цирроза печени.

 

Об авторах

В. В. Бредер
ФГБУ “Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина” Минздрава России
Россия

Бредер Валерий Владимирович – доктор медицинских наук, ведущий научный сотрудник отделения химиотерапии №17 НИИ клинической онкологии им. Н.Н. Трапезникова

115478, Москва, Каширское шоссе, д. 24



М. В. Натрусова
Московский государственный университет имени М.В. Ломоносова
Россия

Натрусова Мария Витальевна – студентка факультета фундаментальной медицины

119991, Москва, Ленинские горы, д. 1



И. А. Джанян
ФГБУ “Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина” Минздрава России
Россия

Джанян Ирина Анатольевна – врач-хирург отделения химиотерапии №17 НИИ клинической онкологии

115478, Москва, Каширское шоссе, д. 24



Список литературы

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394–424. https://doi.org/10.3322/caac.21492.

2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018; 68 (1): 7–30. https://doi.org/10.3322/caac.21442.

3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56 (4): 908–943. https://doi.org/10.1016/j.jhep.2011.12.001.

4. Boland P., Wu J. Systemic therapy for hepatocellular carcinoma: beyond sorafenib. Chin. Clin.Oncol. 2018; 7 (5): 50. https://doi.org/10.21037/cco.2018.10.10.

5. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359 (4): 378–390.

6. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34.

7. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, version 3.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.

8. Marrero J.A., Kudo M., Venook A.P., Ye S.L., Bronowicki J.P., Chen X.P., Dagher L., Furuse J., Geschwind J.H., de Guevara L.L., Papandreou C., Takayama T., Sanyal A.J., Yoon S.K., Nakajima K., Lehr R., Heldner S., Lencioni R. Observational registry of sorafenib use in clinical practice across Child–Pugh subgroups: the GIDEON study. J. Hepatol. 2016; 65 (6): 1140–1147. https://doi.org/10.1016/j.jhep.2016.07.020

9. Matsuki M., Adachi Y., Ozawa Y., Kimura T., Hoshi T., Okamoto K., Tohyama O., Mitsuhashi K., Yamaguchi A., Matsui J., Funahashi Y. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Sci. 2017; 108 (4): 763–771. https://doi.org/10.1111/cas.13169

10. Bruix J., Qin S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., Gerolami R., Masi G., Ross P.J., Song T., Bronowicki J.P., OllivierHourmand I., Kudo M., Cheng A.L., Llovet J.M., Finn R.S., LeBerre M.A., Baumhauer A., Meinhardt G., Han G. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9

11. Abou-Alfa G.K., Meyer T., Cheng A.L., El-Khoueiry A.B., Rimassa L., Ryoo B.Y., Cicin I., Merle P., Chen Y., Park J.W., Blanc J.F., Bolondi L., Klümpen H.J., Chan S.L., Zagonel V., Pressiani T., Ryu M.H., Venook A.P., Hessel C., BorgmanHagey A.E., Schwab G., Kelley R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018; 379 (1): 54–63. https://doi.org/10.1056/NEJMoa1717002

12. Kudo M. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology. 2017; 93 Suppl 1: 135–146. https://doi.org/10.1159/000481244

13. El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., Kim T.Y., Choo S.P., Trojan J., Welling T.H., Meyer T., Kang Y.K., Yeo W., Chopra A., Anderson J., Dela Cruz C., Lang L., Neely J., Tang H., Dastani H.B., Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389 (10088): 2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2

14. Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D., Verslype C., Zagonel V., Fartoux L., Vogel A., Sarker D., Verset G., Chan S.L., Knox J., Daniele B., Webber A.L., Ebbinghaus S.W., Ma J., Siegel A.B., Cheng A.L., Kudo M. KEYNOTE-224 investigators. KEYNOTE-224 Investi gators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19 (7): 940–952. https://doi.org/10.1016/S1470-2045(18)30351-6

15. Finn R.S., Ryoo B.Y., Merle P., Kudo M., Bouattour M., Lim H.Y., Breder V., Edeline J., Chao Y., Ogasawara S., Yau T., Garrido M., Chan S.L., Knox J., Daniele B., Ebbinghaus S.W., Chen E., Siegel A.B., Zhu A.X., Cheng A.L. KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J. Clin. Oncol. 2020; 38 (3): 193–202. https://doi.org/10.1200/JCO.19.01307

16. Zhu A.X., Galle P.R., Kudo M., Finn R.S., Yang L., Abada P., Llovet J.P. A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib (REACH-2). J. Clin. Oncol. 2017; 34 (15_suppl): TPS4145-TPS4145. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS4145

17. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19 (3): 329–338.

18. Eilard M.S., Andersson M., Naredi P., Geronymakis C., Lindnér P., Cahlin C., Bennet W., Rizell M. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer. 2019; 19 (1): 568. https://doi.org/10.1186/s12885-019-5760-8

19. Hoffmann K., Glimm H., Radeleff B., Richter G., Heining C., Schenkel I., Zahlten-Hinguranage A., Schirrmacher P., Schmidt J., Büchler M.W., Jaeger D., Kalle C., Schemmer P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008; 8: 349. https://doi.org/10.1186/1471-2407-8-349

20. Yin J., Li N., Han Y., Xue J., Deng Y., Shi J., Guo W., Zhang H., Wang H., Cheng S., Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two stage longitudinal clinical study. J. Clin. Oncol. 2013; 31 (29): 3647–3655. https://doi.org/10.1200/JCO.2012.48.5896

21. Bruix J., Takayama T., Mazzaferro V., Chau G.Y., Yang J., Kudo M., Cai J., Poon R.T., Han K.H., Tak W.Y., Lee H.C., Song T., Roayaie S., Bolondi L., Lee K.S., Makuuchi M., Souza F., Berre M.A., Meinhardt G., Llovet J.M. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16 (13): 1344–1354. https://doi.org/10.1016/S1470-2045(15)00198-9

22. Zhuang L., Zeng X., Yang Z., Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and metaanalysis. PLoS One. 2013; 8 (9): e61361. https://doi.org/10.1371/journal.pone.0061361

23. Lu L.C., Cheng A.L., Poon R.T. Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin. Liver Dis. 2014; 34 (4): 427–434. https://doi.org/10.1055/s-0034-1394141

24. Okita K., Izumi N., Matsui O., Tanaka K., Kaneko S., Moriwaki H., Ikeda K., Osaki Y., Numata K., Nakachi K., Kokudo N., Imanaka K., Nishiguchi S., Okusaka T., Nishigaki Y., Shiomi S., Kudo M., Ido K., Karino Y., Hayashi N., Ohashi Y., Makuuchi M., Kumada H. Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J. Gastroenterol. 2015; 50 (2): 191–202. https://doi.org/10.1007/s00535-014-0956-9

25. Yoshida H., Shiratori Y., Kudo M., Shiina S., Mizuta T., Kojiro M., Yamamoto K., Koike Y., Saito K., Koyanagi N., Kawabe T., Kawazoe S., Kobashi H., Kasugai H., Osaki Y., Araki Y., Izumi N., Oka H., Tsuji K., Toyota J., Seki T., Osawa T., Masaki N., Ichinose M., Seike M., Ishikawa A., Ueno Y., Tagawa K., Kuromatsu R., Sakisaka S., Ikeda H., Kuroda H., Kokuryu H., Yamashita T., Sakaida I., Katamoto T., Kikuchi K., Nomoto M., Omata M. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011; 54 (2): 532–540. https://doi.org/10.1002/hep.24430

26. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356 (9232): 802–807.

27. Clinical Тrials. gov: database of privately and publicly funded clinical studies conducted around the world. URL:https://clinicaltrials.gov

28. Satapathy S.K., Das K., Kocak M., Helmick R.A., Eason J.D., Nair S.P., Vanatta J.M. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant. 2018; 32 (5): e13246. https://doi.org/10.1111/ctr.13246

29. Vogel A., Cervantes A., Chau I., Daniele B., Llovet J.M., Meyer T., Nault J.-C., Neumann U., Ricke J., Sangro B., Schirmacher P., Verslype C., Zech C.J., Arnold D., Martinelli E. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018; 29 (Supplement 4): iv238–iv255. https://doi.org/10.1093/annonc/mdy308

30. Wang B., Xu H., Gao Z.Q., Ning H.F., Sun Y.Q., Cao G.W. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008; 49 (5): 523–529. https://doi.org/10.1080/02841850801958890

31. Meyer T., Fox R., Ma Y.T., Ross P.J., James M.W., Sturgess R., Stubbs C., Stocken D.D., Wall L., Watkinson A., Hacking N., Evans T.R.J., Collins P., Hubner R.A., Cunningham D., Primrose J.N., Johnson P.J., Palmer D.H. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2017; 2 (8): 565–575. https://doi.org/10.1016/S2468-1253(17)30156-5

32. Li L., Zhao W., Wang M., Hu J., Wang E., Zhao Y., Liu L. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018; 18 (1): 138. https://doi.org/10.1186/s12876-018-0849-0

33. Kudo M., Ueshima K., Ikeda M., Torimura T., Tanabe N., Aikata H., Izumi N., Yamasaki T., Nojiri S., Hino K., Tsumura H., Kuzuya T., Isoda N., Yasui K., Aino H., Ido A., Kawabe N., Nakao K., Wada Y., Yokosuka O., Yoshimura K., Okusaka T., Furuse J., Kokudo N., Okita K., Johnson P.J., Arai Y., TACTICS study group. Randomised, multicentre prospective trial of transarterialchemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; pii: gutjnl-2019-318934. https://doi.org/10.1136/gutjnl-2019-318934

34. Reig M. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC refined RECIST. Semin. Liver Dis. 2014; 34 (4): 445–455. https://doi.org/10.1055/s-0034-1394143

35. Бредер В.В., Лактионов К.К. Системная терапия гепатоцеллюлярного рака: достижения и перспективы. Практическая онкология. 2019; 20 (3): 232–242. https://doi.org/10.31917/2003232

36. Yau T., Park J.W., Finn R.S., Cheng A.-L., Mathurin P., Edeline J., Kudo M., Han K., Harding J.J., Merle P., Rosmorduc O., Wyrwicz L., Schott E., Choo S.P., Kelley R.K., Begic D., Chen G., Neely J., Anderson J., Sangro B. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol. 2019; 30 (suppl_5): v851–v934. https://doi.org/10.1093/annonc/mdz394

37. Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Piscaglia F., Baron A., Park J.W., Han G., Jassem J., Blanc J.F., Vogel A., Komov D., Evans T.R.J., Lopez C., Dutcus C., Guo M., Saito K., Kraljevic S., Tamai T., Ren M., Cheng A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391 (10126): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1

38. Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Cheng A.L., Piscaglia F., Ueshima K., Aikata H., Vogel A., López C.L., Pracht M., Meng Z., Daniele B., Park J.W., Palmer D.H., Dutcus C.E., Tamai T., Saito K., Lencioni R. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J. Clin. Oncol. 2019; 37 (4_suppl): 186–186. https://doi.org/10.1200/JCO.2019.37.4_suppl.186

39. Yoong K.F., McNab G., Hübscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumorinfiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 1998; 160 (8): 3978–3988.

40. Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 2010; 10 (11): 753–766.

41. Cheng A.L., Qin S., Ikeda M., Qin S., Ikeda M., Galle P., Ducreux M., Zhu A.,Kim T-Y., Kudo M., Breder V., Merle P., Kaseb A., Li D., Verret W., Xu Z., Hernandez S., Liu J., Huang C., Mulla S., Lim H.Y., Finn R.I. Mbrave 150: Efficacy and safety results from a phase 3 study evaluating atezolizumab + bevacizumab vs sorafenib as first treatment for patients with unresectable hepatocellular carcinoma. Ann. Oncol. 2019 (early release online).

42. Ogasawara S., Chiba T., Ooka Y., Suzuki E., Maeda T., Yokoyama M., Wakamatsu T., Inoue M., Saito T., Kobayashi K., Kiyono S., Nakamura M., Nakamoto S., Yasui S., Tawada A., Arai M., Kanda T., Maruyama H., Yokosuka O., Kato N. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest. New Drugs. 2018; 36 (2): 332–339. https://doi.org/10.1007/s10637-017-0507-3

43. Finn R.S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Gerolami R., Caparello C., Cabrera R., Chang C., Sun W., LeBerre M.A., Baumhauer A., Meinhardt G., Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J. Hepatol. 2018; 69 (2): 353–358. https://doi.org/10.1016/j.jhep.2018.04.010

44. Harding J.J., Nandakumar S., Armenia J., Khalil D.N., Albano M., Ly M., Shia J., Hechtman J.F., Kundra R., El Dika I., Do R.K., Sun Y., Kingham T.P., D'Angelica M.I., Berger M.F., Hyman D.M., Jarnagin W., Klimstra D.S., Janjigian Y.Y., Solit D.B., Schultz N., Abou-Alfa G.K. Prospective genotyping of hepatocellular carcinoma: clinical implications of next generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 2019; 25 (7): 2116–2126. https://doi.org/10.1158/1078-0432.CCR-18-2293

45. Alsina A., Kudo M., Vogel A., Cheng A.L., Tak W.Y., Ryoo B.Y., Evans J., López C.L., Daniele B., Misir S., Ren M., Izumi N., Qin S., Finn R.S. Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2019; 37 (4_suppl): 371–371. https://doi.org/10.1200/JCO.2019.37.4_suppl.371

46. Rahimi R.S., Trotter J.F. Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann. Gastroenterol. 2015; 28 (3): 323–330. PMID: 26130250

47. Iavarone M., Invernizzi F., Czauderna C., Sanduzzi-Zamparelli M., Bhoori S., Amaddeo G., Manini M.A., López M.F., Anders M., Pinter M., Rodríguez M.J.B., Cristóbal M.R., Soteras G.A., Piñero F., Villadsen G.E., Weinmann A., Crespo G., Mazzaferro V., Regnault H., Giorgio M., González-Diéguez M.L., Donato M.F., Varela M., Wörns M.A., Bruix J., Lampertico P., Reig M. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am. J. Transplant. 2019; 19 (11): 3176–3184. https://doi.org/10.1111/ajt.15551

48. Gassmann D., Weiler S., Mertens J.C., Reiner C.S., Vrugt B., Nägeli M., Mangana J., Müllhaupt B., Jenni F., Misselwitz B. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant. Direct. 2018; 4 (8): e376. https://doi.org/10.1097/TXD.0000000000000814

49. Kudo M., Matilla A., Santoro A., Melero I., Gracian A.C., Acosta-Rivera M., Choo S., El-Khoueiry A.B., Kuromatsu R., El-Rayes B.F., Numata K., Itoh Y., Costanzo F.D., Crysler O.V., Reig M., Shen Y., Neely J., Cruz C.M.D., Baccan C., Sangro B. Nivolumab in patients with Сhild-Рugh В advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study. J. Clin. Oncol. 2019; 37 (4_suppl): 327–327. https://doi.org/10.1200/JCO.2019.37.4_suppl.327

50. Pishvaian M.J., Lee M.S., Ryoo B-Y., Stein S., Lee K.H., Verret W., Spahn J., Shao H., Liu B., Iizuka K., Hsu C.H. LBA26 Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann. Oncol. 2018; 29 (suppl_8). https://doi.org/10.193/annonc/mdy424.028

51. Kelley R.K., Abou-Alfa G.K., Bendell J.C., Kim T.Y., Borad M.J., Yong W.P., Morse M., Kang Y.K., Rebelatto M., Makowsky M., Xiao F., Morris S.R., Sangro B. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J. Clin. Oncol. 2017; 35 (15_suppl): 4073–4073. https://doi.org/10.1200/JCO.2017.35.15_suppl.4073

52. Ikeda M., Sung M.W., Kudo M., Kobayashi M., Baron A.D., Finn R.S., Kaneko S., Zhu A., Kubota T., Kraljevic S., Ishikawa K., Siegel A.B., Kumada H., Okusaka T.A. Phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J. Clin. Oncol. 2018; 36 (15_suppl): 4076. https://doi.org/10.1200/JCO.2018.36.15_suppl.4076

53. Xu J.M., Zhang Y., Jia R., Wang Y., Liu R., Zhang G., Zhao C., Zhang Y., Zou J., Wang Q. Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial. J. Clin. Oncol. 2018; 36 (15_suppl): 4075. https://doi.org/10.1200/JCO.2018.36.15_suppl.4075

54. Abou-Alfa G.K., Chan S.L., Furuse J., Galle P.R., Kelley R.K., Qin S., Armstrong J., Darilay A., Vlahovic G., Negro A., Sangro B. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J. Clin. Oncol. 2018; 36 (15_suppl): TPS4144-TPS4144. https://doi.org/10.1200.JCO.2018.36.15_suppl. TPS4144

55. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L., Lao C.D., Wagstaff J., Schadendorf D., Ferrucci P.F., Smylie M., Dummer R., Hill A., Hogg D., Haanen J., Carlino M.S., Bechter O., Maio M., MarquezRodas I., Guidoboni M., McArthur G., Lebbé C., Ascierto P.A., Long G.V., Cebon J., Sosman J., Postow M.A., Callahan M.K., Walker D., Rollin L., Bhore R., Hodi F.S., Larkin J. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 2017; 377 (14): 1345–1356. https://doi.org/10.1056/NEJMoa1709684

56. Motzer R.J., Tannir N.M., McDermott D.F., ArénFrontera O., Melichar B., Choueiri T.K., Plimack E.R., Barthélémy P., Porta C., George S., Powles T., Donskov F., Neiman V., Kollmannsberger C.K., Salman P., Gurney H., Hawkins R., Ravaud A., Grimm M.O., Bracarda S., Barrios C.H., Tomita Y., Castellano D., Rini B.I., Chen A.C., Mekan S., McHenry M.B., Wind-Rotolo M., Doan J., Sharma P., Hammers H.J., Escudier B. CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 2018; 378 (14): 1277–1290. https://doi.org/10.1056/NEJMoa1712126

57. Hellmann M.D., Ciuleanu T.E., Pluzanski A., Lee J.S., Otterson G.A., Audigier-Valette C., Minenza E., Linardou H., Burgers S., Salman P., Borghaei H., Ramalingam S.S., Brahmer J., Reck M., O'Byrne K.J., Geese W.J., Green G., Chang H., Szustakowski J., Bhagavatheeswaran P., Healey D., Fu Y., Nathan F., Paz-Ares L. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 2018; 378 (14): 2093–2104. https://doi.org/10.1056/NEJMoa1801946

58. Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology. 2017; 92 (Supple 1): 50–62. https://doi.org/10.1159/000451016

59. Казанцева М.А., Бредер В.В., Лактионов К.К. Иммунотерапия гепатоцеллюлярного рака: начало и перспективы. Медицинский совет. 2019; 10: 15–21. https://doi.org/10.21518/2079-701X-2019-10-15-21

60. Kaseb A., Duda D.G., Tran Cao H.S., Abugaba Y.I., Vence L.M., Rashid A., CarmagnaniPestana R., Blando J.M., Singh S., Vauthey J.N., Chun Y.S., Tzeng C.D., Sakamuri D., Wolff R.A., Yao J.C., Allison J., Sharma P. Open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patient with resectable HCC. Ann. Oncol. 2019; 30 (suppl_5): v851–v934. https://doi.org/10.1093/annonc/mdz394


Для цитирования:


Бредер В.В., Натрусова М.В., Джанян И.А. Терапия гепатоцеллюлярного рака: реалии и перспективы. Анналы хирургической гепатологии. 2020;25(2):27-38. https://doi.org/10.16931/1995-5464.2020227-38

For citation:


Breder V.V., Natrusova M.V., Dzhanyan I.A. Systemic therapy of hepatocellular carcinoma: reality and prospects. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2020;25(2):27-38. (In Russ.) https://doi.org/10.16931/1995-5464.2020227-38

Просмотров: 184


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5464 (Print)
ISSN 2408-9524 (Online)